A Tender Sinus does not Always Mean Rhinosinusitis

2002 ◽  
Vol 127 (5) ◽  
pp. 387-397 ◽  
Author(s):  
K. Naranch ◽  
Y.-J. Park ◽  
M.S. Repka-Ramirez ◽  
A. Velarde ◽  
D. Clauw ◽  
...  

BACKGROUND: Sinus tenderness has not been quantitatively assessed. OBJECTIVE: We sought to compare sinus and systemic tenderness in rhinosinusitis, allergic rhinitis, and chronic fatigue syndrome (CFS), and healthy (non-CFS) groups. METHODS: Cutaneous pressures (kg/cm2) causing pain at 5 sinus and 18 systemic sites were measured in acute and chronic rhinosinusitis, active allergic rhinitis, healthy non-CFS/no rhinosinusitis, and CFS subjects. RESULTS: Sinus thresholds differed significantly ( P ≤ 10−11, ANOVA) between non-CFS/no rhinosinusitis (1.59 ± 0.14 kg/cm2, mean ± 95% CI, n = 117), allergic rhinitis (1.19 ± 0.31, n = 30), exacerbations of chronic rhinosinusitis (1.25 ± 0.26, n = 25), non-CFS/chronic rhinosinusitis (1.23 ± 0.27, n = 23), acute rhinosinusitis (1.10 ± 0.20, n = 22), CFS/no rhinosinusitis (0.98 ± 0.15, n = 70), and CFS/chronic rhinosinusitis (0.78 ± 0.12, n = 56). Systemic pressure thresholds were lower for CFS (1.46 ± 0.15) than for non-CFS (2.67 ± 0.22, P ≤ 10−11). CONCLUSIONS: The lower sinus thresholds of rhinosinusitis groups validated the sign of sinus tenderness. Sinus and systemic thresholds were both 44% lower in CFS than in non-CFS subjects, suggesting that systemic hyperalgesia contributed to CFS sinus tenderness and “rhinosinusitis” complaints. Tenderness to palpation or percussion is one of the clinical hallmarks of acute and chronic rhinosinusitis. 1,2 This sign may equate with the subjective sensation of pain experienced by rhinosinusitis subjects and so may be indicative of either excessive nociceptive nerve depolarization or centrally mediated hyperalgesia. Several peripheral mechanisms may contribute, including the release of excessive amounts of mediators that activate sensory neurons (eg, bradykinin); increased sensitivity of type C fibers to mediators generated during acute or chronic inflammation (eg, endothelin, bradykinin); or hyperresponsiveness due to facilitation of neural depolarization induced by prostaglandins, leukotriene B4, and neurotropic cytokines (eg, nerve growth factor). 3 Central factors may also cause hyperalgesia by modulating the spinal cord actions of large-diameter, low-threshold A$bT-fiber touch or other sensory nerves that innervate the trigeminal dermatome and mucosal areas (“ mucotome”). Sites of alteration may include the spinal dorsal horn somatosensory region and higher central nervous system sites of nociceptive regulation 4 and dysfunction of descending antinociceptive aminergic neural circuits. 3 Although the sign of tenderness is commonly used to diagnose rhinosinusitis, the degree of hyperalgesia has not been quantified in comparison to the sensitivity of control subjects. Therefore, we used dolorimetry (algometry) to measure sinus tenderness. 4 A strain gauge was pressed against the sinus regions until pain was elicited. The mean pressure required to cause pain was considered to be the sinus pressure threshold (kg/cm2). Systemic pressure threshold was determined for 18 “tender points” that are used to diagnose fibromyalgia. 4 Sinus and systemic tenderness were compared in acute rhinosinusitis, chronic rhinosinusitis, chronic rhinosinusitis with acute exacerbations, active allergic rhinitis, and control groups. Chronic fatigue syndrome (CFS) subjects formed one control group. They have a high prevalence of rhinitis complaints (60% to 80%) but there is no evidence of mucosal inflammation based on measures of mucus constituents including neutrophil elastase and eosinophil cationic protein, 5 cytokines, 6 or any bias toward atopic disease as assessed by serum IgE levels. 4 Another reference population consisted of healthy subjects not fulfilling the criteria for CFS (non-CFS subjects). The impact of chronic rhinosinusitis complaints was assessed in CFS/chronic rhinosinusitis, non-CFS/chronic rhinosinusitis, and their corresponding no-rhinosinusitis subpopulations.

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e041947
Author(s):  
Pamela G Mckay ◽  
Helen Walker ◽  
Colin R Martin ◽  
Mick Fleming

ObjectiveTo explore the relationship between symptoms of chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) and fibromyalgia (FM). The hypothesis predicated that there would be no significant differences between the group’s symptom experience.DesignA quasiexperimental design. Structural equation modelling (SEM) and invariance testing.ParticipantsMales (M) and females (F) >16 with a confirmed diagnosis of CFS/ME or FM by a general practitioner or specialist. CFS/ME (n=101, F: n=86, M: n=15, mean (M) age M=45.5 years). FM (n=107, F: n=95, M: n=12, M=47.2 years).Outcome measuresDiagnostic criteria: the American Centers for Disease Control and Prevention (CDC) for CFS/ME and the American College of Rheumatology (ACR) criteria for FM. Additional symptom questionnaires measuring: pain, sleep quality, fatigue, quality of life, anxiety and depression, locus of control and self-esteem.ResultsInvariance was confirmed with the exception of the American CDC Symptom Inventory, Fibromyalgia Impact Questionnaire and Hospital Anxiety and Depression Scale (p<0.05) based on five questions. Consequently, it was erroneous to conclude differences. Therefore, the Syndrome Model was created. SEM could not have tested the ACR previously, as it comprised a single data point. Thus, it was combined with these three questionnaires, increasing the data points, to create this new measurable model. Results confirmed no significant differences between groups (p=0.07 (p<0.05)).ConclusionParticipants responded in a similar manner to the questionnaire, confirming the same symptom experience. It is important to consider this in context with differing criteria and management guidelines, as this may influence diagnosis and the trajectory of patient’s management. With the biomedical cause currently unclear, it is the symptom experience and the impact on quality of life that is important. These findings are meaningful for patients, clinicians and policy development and support the requirement for future research.


2018 ◽  
Vol 27 (2) ◽  
pp. 188-196 ◽  
Author(s):  
Jeroen J. Roor ◽  
Hans Knoop ◽  
Brechje Dandachi-FitzGerald ◽  
Maarten J.V. Peters ◽  
Gijs Bleijenberg ◽  
...  

Healthcare ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1546
Author(s):  
Helen Brownlie ◽  
Nigel Speight

The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated. Our analysis is consistent with the propositions that: (1) IgG is highly effective for a proportion of patients with severe and well-characterised ME/CFS; (2) responders can be predicted with a high degree of accuracy based on markers of immune dysfunction. Rigorous steps were taken in the research trials to record adverse events, with transient symptom exacerbation commonly experienced in both intervention and placebo control groups, suggesting that this reflected the impact of participation on people with an illness characterised by post-exertional symptom exacerbation. Worsening of certain specific symptoms, notably headache, did occur more commonly with IgG and may have been concomitant to effective treatment, being associated with clinical improvement. The findings emerging from this review are supported by clinical observations relating to treatment of patients with severe and very severe ME/CFS, for whom intramuscular and subcutaneous administration provide alternative options. We conclude that: (1) there is a strong case for this area of research to be revived; (2) pending further research, clinicians would be justified in offering a course of IgG to selected ME/CFS patients at the more severe end of the spectrum. As the majority of trial participants had experienced an acute viral or viral-like onset, we further suggest that IgG treatment may be pertinent to the care of some patients who remain ill following infection with SARS-CoV-2 virus.


2018 ◽  
Vol 33 (6) ◽  
pp. 372-379 ◽  
Author(s):  
Kenneth J. Friedman ◽  
Beth Mattey ◽  
Faith Newton

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic illness that is defined and diagnosed by its symptoms: extreme fatigue made worse by physical and mental activity, pain and decreased mental stamina, among others. A long-held, erroneous belief that ME/CFS is not a physiological illness has persisted among some clinicians, leading to the denial of a patient’s physical illness and attributing the symptoms to other causes. The debilitating effects of ME/CFS in the pediatric population can affect all aspects of academic, social, emotional, and physical development. ME/CFS has been diagnosed in children younger than 10 years. Therefore, the school nurse is likely to encounter one or more students in the various stages of this disease, putting the school nurse in a position to ameliorate the impact of this potentially devastating chronic condition.


2018 ◽  
Vol 2 (1) ◽  
pp. e000281 ◽  
Author(s):  
Roxanne M Parslow ◽  
Nina Anderson ◽  
Danielle Byrne ◽  
Alison Shaw ◽  
Kirstie L Haywood ◽  
...  

ObjectiveAs part of a larger qualitative study to explore outcomes important in paediatric chronic fatigue syndrome/myalgic encephalopathy (CFS/ME) and what improvements in fatigue and disability are key, interviews were undertaken with adolescents and their parents. This paper focuses on their descriptions of fatigue, fluctuation of symptoms and payback.Design and settingSemistructured qualitative interviews were undertaken between December 2014 and February 2015. Adolescents and parents were interviewed separately. Participants were recruited from a single specialist paediatric chronic fatigue service. Interviews were audio recorded, transcribed verbatim and analysed using thematic analysis.ParticipantsWe interviewed 21 adolescents and their parents (20 mothers and 2 fathers). The adolescents were aged between 12 and 17 years of age (mean age 14.4 years), mild to moderately affected by CFS/ME (not housebound) and the majority were female (16/21).ResultsAll adolescents with CFS/ME reported fatigue, a natural fluctuation of the condition, with good days and bad days as well as an increase in symptoms after activity (payback). However, adolescent’s descriptions of fatigue, symptoms and the associated impact on their daily lives differed. The variations included: fatigue versus a collection of symptoms, constant versus variable symptoms and variable symptom severity. There were differences between participants in the amount of activity taken to cause payback. The impact of fatigue and symptoms on function ranged from: limiting the duration and amount of leisure activities, struggling with daily activities (eg, self-care) to no activity (sedentary).ConclusionsFatigue, fluctuation of the condition and payback after activity are described by all adolescents with CFS/ME in this study. However, the individual experience in terms of how they describe it and the degree and impact varies.


PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0156120
Author(s):  
Lucy P. Goldsmith ◽  
Graham Dunn ◽  
Richard P. Bentall ◽  
Shôn W. Lewis ◽  
Alison J. Wearden

2005 ◽  
Vol 187 (2) ◽  
pp. 184-185 ◽  
Author(s):  
Judith Prins ◽  
Gijs Bleijenberg ◽  
Eufride Klein Rouweler ◽  
Jos Van Der Meer

SummaryPsychiatric disorders have been associated with poor outcome in individuals with chronic fatigue syndrome (CFS). This study examines the impact of psychiatric disorders on outcome of cognitive-behavioural therapy (CBT). Psychiatric diagnoses were assessed with a structured psychiatric interview in a CBT trial of 270 people with CFS. Lifetime and current psychiatric disorders were found in 50 and 32% respectively. No significant differences in fatigue severity and functional impairment following treatment were found between participants with and without psychiatric diagnoses.


2013 ◽  
Vol 61 (7) ◽  
pp. 299-307 ◽  
Author(s):  
Samantha Flores ◽  
Abigail Brown ◽  
Samuel Adeoye ◽  
Leonard A. Jason ◽  
Meredyth Evans

2013 ◽  
Vol 61 (7) ◽  
pp. 299-307 ◽  
Author(s):  
Samantha Flores ◽  
Abigail Brown ◽  
Samuel Adeoye ◽  
Leonard A. Jason ◽  
Meredyth Evans

Sign in / Sign up

Export Citation Format

Share Document